Most patients with diabetes develop insulin resistance about one year before they start to develop Type 2 diabetes. From a single transverse diabetic rat model deprived of oxygen for several weeks researchers have outlined a new mechanism that could make it possible to support the repair of insulin-producing cells in diabetes patients.
Endoplasmic Reticulum Amparo (ERAM) a tiny region in the cell nucleus plays an important role in the regulation of many important processes within cells including gene transcriptional control transformation of internal processes and integration of signals. One of ERAMs roles is to support cell differentiation.
By removing the blood vessels of the kidneys the kidneys act as an organ pump to take up oxygen. Cells in the kidney represent a vast and complex area containing a mixed population of guidelines and domestic species making it tough for researchers to simply identify physiological or pathogenic ERAMs and test ways to punish them.
Led by researcher Scott Kilbane who won the 2017 Nobel Prize in Physiology or Medicine the Kilbane laboratory in Japan developed a molecular way to determine not only when ERAMs can cause cell death but also whether cells regenerate. The team found that ERAMs hijack the regeneration process to get the best jobs done. This function helps treat diabetes by promoting the kidneys to send repair signals to the blood vessels then initiating a repair response before the health is compromised.
Our results provide evidence that ERAMs induce damage and indicate potential application to the treatment of Type 2 diabetes where we believe ERAM-related mitochondrial injury could serve as a useful way of supporting the regeneration of insulin-producing stem cells.
Scott Kilbane researcher Nobel Prize-winner Professor Department of Cellular Biology Duke University.
Kilbanes team developed a mouse ERAM model dependent on ERAM1 which is localized to the sole artery in the kidney. ERAM1 is widely distributed across the organ causing blood vessels to become damaged due to disabled ERAM1. These liver-injured ERAMs tend to remain active but end up firing or dying and are eventually eliminated.
While our ERAM experiment is novel we believe the principle principles of this basic concept are applicable not only to ERAM1-deficient transplant models of kidney disease but to ERAM1-deficient transplant models of many organs or tissues says Kilbane who is the studys senior author.